UNI-494 was well-tolerated as a single dose up to 160 mg and in multiple doses at 40 mg twice-a-day ... Kidney Week 2024 ...

Belzutifan has a “generally manageable” safety profile in patients with RCC, with a relatively low rate of treatment discontinuation.

The combination of sitravatinib, nivolumab, and ipilimumab appears safe and active in patients with advanced clear cell renal cell carcinoma (ccRCC), according to research presented in a poster at ...

CAMBRIDGE, Mass., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today reported financial results for the three-month period ended ...

Preliminary results from Phase 1 ACESOT-1051 trial of WEE1 inhibitor, APR-1051, demonstrate the product to be well-tolerated with no unexpected ...

Q3 2024 Earnings Call Transcript November 7, 2024 4:30 AM ETCompany ParticipantsBruce Mackle - LifeSci Advisors, ...

Exacerbations of the chronic and progressive inflammatory disease bronchiectasis can impact quality of life. Treatment, based ...

German Chancellor Olaf Scholz has summoned Finance Minister Christian Lindner and Economy Minister Robert Habeck for ...

Results demonstrated the mean total medical costs per patient per year decreased significantly after patients began ...

Trump's US election win offers key insights into messaging and voter focus, affecting global liberals. US election results: ...

After dosing with Cognition’s CT1812, study reports declines of 95% and higher in subgroup with below-median p-tau217.